Pharmacokinetics, pharmacodynamics, and tolerability of PSI 7851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection

Trial Profile

Pharmacokinetics, pharmacodynamics, and tolerability of PSI 7851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2013

At a glance

  • Drugs PSI 7851 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 22 Mar 2013 Status changed from recruiting to completed.
    • 31 Jul 2009 Positive preliminary results announced in a Pharmasset media release.
    • 15 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top